What is less recognised in conventional medicine is the concept of subclinical systemic overgrowth, where Candida proliferates throughout the gut without producing the obvious localized infections such as oral thrush or vaginal candidiasis that conventional physicians routinely diagnose and treat
5,12,13 These efforts have yielded six GLP-1 RAsstarting with the development of exendin-4 (Figure 1B)-based exenatide (Figure 1C), followed by liraglutide (Figure 1D), albiglutide, dulaglutide (Figure 1E), lixisenatide, and semaglutide (Figure 1F)that have been approved by the United States Food and Drug Administration (US FDA) to treat type 2 diabetes
These changes may help restore central energy homeostasis and explain the marked weight loss observed even at moderate GE doses (Schwenk et al., 2015)
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
A comprehensive safety and tolerability study evaluated approximately 900 participants across six trials with the following protocols: Subcutaneous/Intravenous Protocols: Single doses ranging from 25 to 400 mcg/kg body weight were tested
